India, April 14 -- Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company developing a pan-NOS inhibitor for advanced breast cancer, has agreed to merge with privately held Obsidian Therapeutics, Inc., a developer of engineered tumor-infiltrating lymphocyte (TIL) cell therapies.
The combined company will operate as Obsidian Therapeutics, Inc. and plans to list on Nasdaq under the ticker "OBX".
Obsidian's lead candidate, OBX-115, is a genetically engineered, autologous TIL therapy currently in a Phase 2 trial for advanced melanoma and a Phase 1 trial for non-small cell lung cancer (NSCLC). The therapy uses Obsidian's cytoDRiVE protein-regulation platform and is designed to improve TIL persistence, eliminate the need f...